SCHEMBL8316063

SCHEMBL8316063

NC(=O)C(N)Cc1cccc2ccccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 1/20 0.55
TDP1 Q9NUW8 1/20 0.51
MTNR1A P48039 1/20 0.51
SLC1A3 P43003 1/20 0.49
SLC1A2 P43004 1/20 0.49
SLC1A1 P43005 1/20 0.49
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PARP10 Q53GL7 1/20 0.47
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46
ACP3 P15309 1/20 0.46
AKT1 P31749 2/20 0.46
ROCK2 O75116 1/20 0.46
PIM1 P11309 1/20 0.46
PRKACA P17612 1/20 0.46
FGFR3 P22607 1/20 0.46
GSK3A P49840 1/20 0.46
RPS6KA3 P51812 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30887331 1.00 CTNNB1 (0.55) CTNNB1TDP1MTNR1ASLC1A3SLC1A2
SCHEMBL29397858 0.86 CTNNB1 (0.59) CTNNB1TDP1SLC1A3SLC1A2SLC1A1
SCHEMBL93516 0.86 CTNNB1 (0.59) CTNNB1TDP1SLC1A3SLC1A2SLC1A1
SCHEMBL29397866 0.86 CTNNB1 (0.59) CTNNB1TDP1SLC1A3SLC1A2SLC1A1
SCHEMBL93515 0.86 CTNNB1 (0.59) CTNNB1TDP1SLC1A3SLC1A2SLC1A1
SCHEMBL29482763 0.86 CTNNB1 (0.59) CTNNB1TDP1SLC1A3SLC1A2SLC1A1
SCHEMBL660499 0.86 CTNNB1 (0.59) CTNNB1TDP1SLC1A3SLC1A2SLC1A1
SCHEMBL1025267 0.86 CTNNB1 (0.59) CTNNB1TDP1SLC1A3SLC1A2SLC1A1
Hydrochloric Acid SCHEMBL30030000 0.85 CTNNB1 (0.58) CTNNB1TDP1SLC1A3SLC1A2SLC1A1
Hydrochloric Acid SCHEMBL5967395 0.85 CTNNB1 (0.58) CTNNB1TDP1SLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1874739-B1 PHARMACEUTICALLY ACTIVE DIAZEPANES NOVARTIS AG (CH) 2010-05-26 EP disclosed
US-20080300237-A1 Pharmaceutically Active Diazepanes OBERHAUSER BERNDT 2008-12-04 US disclosed
US-20080300237-A1 Pharmaceutically Active Diazepanes OBERHAUSER BERNDT 2008-12-04 US disclosed
US-7419976-B2 Diazepanes derivatives useful as IFA inhibitors NOVARTIS AG (CH) 2008-09-02 US disclosed
US-7419976-B2 Diazepanes derivatives useful as IFA inhibitors NOVARTIS AG (CH) 2008-09-02 US disclosed
WO-2004065382-A1 DIAZEPANES DERIVATIVES USEFUL AS LFA INHIBITORS NOVARTIS AG (CH) 2004-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300237-A1 Pharmaceutically Active Diazepanes VCAM1, ICAM1, CD69 CTNNB1 379/4885TDP1 2276/4885MTNR1A 1059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.